Correspondence 0001193125-22-282411 from Pyxis Oncology, Inc. (PYXS) (CIK 0001782223) (PYXS)
Pyxis Oncology, Inc. (PYXS) (CIK 0001782223)
Date: Nov. 10, 2022 · CIK: 0001782223 · Accession: 0001193125-22-282411
AI Filing Summary & Sentiment
File numbers found in text: 333-268100
Letter
Re: Acceleration Request for Pyxis Oncology, Inc.
November 10, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Lauren Hamill
Registration Statement on Form S-3 (File No. 333-268100)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-268100 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on November 14, 2022, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651.
[Signature Page Immediately Follows]
Very truly yours,
/s/ Pamela Connealy
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 10, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Acceleration Request for Pyxis Oncology, Inc. Registration Statement on Form S-3 (File No. 333-268100) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-268100 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on November 14, 2022, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651. [Signature Page Immediately Follows] Very truly yours, /s/ Pamela Connealy Pamela Connealy Chief Financial Officer cc: Lara Sullivan, Pyxis Oncology, Inc. Asher Rubin, Sidley Austin LLP Frank Rahmani, Sidley Austin LLP Istvan A. Hajdu, Sidley Austin LLP